CCDRD

CCDRD

Munich, Germany· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

CCDRD AG is an established, Germany-based contract research organization (CRO) founded in 1990, with operational headquarters in Hoppegarten near Berlin. The company offers full-service clinical trial management (Phases I-IV) and regulatory consulting for pharmaceutical and biotech clients of all sizes, focusing on achieving marketing authorizations globally. Its expertise spans major therapeutic areas and specialized product types, including biosimilars and inhalation products, leveraging a network of clinical sites across Europe and Asia. As a service provider, its success is tied to the broader R&D outsourcing trends in the pharmaceutical industry.

Drug DeliveryMedical Devices

Technology Platform

Integrated clinical research and regulatory services platform for Phase I-IV trials, specializing in bioavailability/bioequivalence, pharmacokinetics, and development of complex dosage forms (inhalation, topical/transdermal).

Opportunities

Growth in biosimilar and complex generic development creates demand for specialized CRO services.
Expansion of clinical trials into Asian markets leverages the company's existing regional network.
Increasing regulatory complexity drives need for integrated regulatory and clinical trial support.

Risk Factors

Faces intense competition from large global and niche CROs.
Revenue is dependent on pharmaceutical R&D spending cycles and client retention.
Operational execution risk and changing international regulations could impact trial costs and timelines.

Competitive Landscape

Operates in the highly competitive global CRO market, competing against large players (e.g., IQVIA, ICON) on scale and technology, and against smaller firms on specialization and cost. Differentiation is likely based on therapeutic/methodological expertise (e.g., biosimilars, inhalation), personalized service, and its established European/Asian network.